mavishhs personal page - To The Moon

mavishhs

mavishhs

No personal profile

30Follow

15Followers

0Topic

0Badge

2021-09-18

Great ariticle, would you like to share it?

Sorry, the original content has been removed

2021-04-26

$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?

2021-04-20

Great ariticle, would you like to share it?

Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate

2021-04-07

hmmm

Sorry, the original content has been removed

2021-04-07

$Tiger Brokers(TIGR)$like my post old haha

2021-03-23

$Mogo Finance Technology Inc.(MOGO)$like me pls

2021-03-09

[OK] [OK] [OK] gogo

2021-03-04

$Tiger Brokers(TIGR)$rest , ready to go

2021-03-01

Great ariticle, would you like to share it?

Sorry, the original content has been removed

2021-02-25

hmmmm

Tesla Temporarily Halts Production at Model 3 Line in California

2021-02-23

[OK] [OK] [OK] [OK]

2021-02-23

Great ariticle, would you like to share it?

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3570762430883798","uuid":"3570762430883798","gmtCreate":1607669310477,"gmtModify":1610530257149,"name":"mavishhs","pinyin":"mavishhs","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":15,"headSize":30,"tweetSize":72,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":884250657,"gmtCreate":1631896562979,"gmtModify":1676530665723,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884250657","repostId":"884264656","repostType":1,"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374051734,"gmtCreate":1619403768828,"gmtModify":1704723308172,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374051734","isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":371159511,"gmtCreate":1618922729333,"gmtModify":1704716907339,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/371159511","repostId":"2128947843","repostType":4,"repost":{"id":"2128947843","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1618914723,"share":"https://ttm.financial/m/news/2128947843?lang=&edition=fundamental","pubTime":"2021-04-20 18:32","market":"us","language":"en","title":"Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2128947843","media":"Benzinga","summary":"Johnson &amp; Johnson (NYSE:JNJ) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.34 by 10.68 percent. This is a 12.61 percent increase over earnings of $2.30 per share from the","content":"<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-20 18:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2128947843","content_text":"Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.Johnson & Johnson Reports 2021 First-Quarter Results:- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpointFIRST-QUARTER 2021 SEGMENT COMMENTARY:Consumer HealthConsumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.PharmaceuticalPharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.Medical DevicesMedical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3557227905112544","authorId":"3557227905112544","name":"ShaunVee","avatar":"https://static.tigerbbs.com/5f64fe4fcaa4f1d2aedde844df964cb4","crmLevel":3,"crmLevelSwitch":0,"idStr":"3557227905112544","authorIdStr":"3557227905112544"},"content":"Vaccine are here to stay, they gonna earn more money In near future i guess..","text":"Vaccine are here to stay, they gonna earn more money In near future i guess..","html":"Vaccine are here to stay, they gonna earn more money In near future i guess.."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341976026,"gmtCreate":1617776262465,"gmtModify":1704702986356,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmm","listText":"hmmm","text":"hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341976026","repostId":"1162389133","repostType":4,"isVote":1,"tweetType":1,"viewCount":615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341062059,"gmtCreate":1617762689971,"gmtModify":1704702790323,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","text":"$Tiger Brokers(TIGR)$like my post old haha","images":[{"img":"https://static.tigerbbs.com/d6460bc8111d6b40363d22d3f8a2998a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341062059","isVote":1,"tweetType":1,"viewCount":718,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":353460824,"gmtCreate":1616513437568,"gmtModify":1704795188865,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","listText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","text":"$Mogo Finance Technology Inc.(MOGO)$like me pls","images":[{"img":"https://static.tigerbbs.com/d1eabf3a50dad90af4a39bd7c5db8334","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353460824","isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323944336,"gmtCreate":1615301275425,"gmtModify":1704780842618,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","text":"[OK] [OK] [OK] gogo","images":[{"img":"https://static.tigerbbs.com/0186365c81b90e76d6a42357df7326ed","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323944336","isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":364902905,"gmtCreate":1614789063307,"gmtModify":1704775350744,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","text":"$Tiger Brokers(TIGR)$rest , ready to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/364902905","isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362819137,"gmtCreate":1614611789329,"gmtModify":1704773099898,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362819137","repostId":"1161689985","repostType":4,"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":361731476,"gmtCreate":1614261074895,"gmtModify":1704769779519,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmmm","listText":"hmmmm","text":"hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/361731476","repostId":"2114131201","repostType":4,"repost":{"id":"2114131201","pubTimestamp":1614247264,"share":"https://ttm.financial/m/news/2114131201?lang=&edition=fundamental","pubTime":"2021-02-25 18:01","market":"us","language":"en","title":"Tesla Temporarily Halts Production at Model 3 Line in California","url":"https://stock-news.laohu8.com/highlight/detail?id=2114131201","media":"Bloomberg","summary":"Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.Workers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation t","content":"<p>Tesla Inc.&nbsp;has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.</p>\n<p>Workers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation time, if they had it.</p>\n<p>Representatives for the Palo Alto, California-based electric carmaker didn’t immediately respond to messages seeking comment.</p>\n<p>While production-line outages aren’t unusual for automakers, they cost the companies revenue. Tesla said last month that it’strying to mitigatethe effects of a global semiconductor shortage on its operations and that it expects to increase global vehicle deliveries by more than 50% this year.</p>\n<p>Hitting maximum deliveries is crucial for Tesla in order for Chief Executive Officer Elon Musk to meet his ambitious goal of selling 20 million cars a year by 2030. Tesla has cut the price of its various models 14 times in markets from China to Japan and France this year, spurring concern it isn’t seeing the volumes desired.</p>\n<p>“When considering Tesla had excess inventory in the fourth quarter of 2020, and has never been able to sell-out its production capacity, we see the company as currently demand constrained, rather than production constrained,” GLJ Research LLC founder Gordon Johnson wrote in a note earlier this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Temporarily Halts Production at Model 3 Line in California</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Temporarily Halts Production at Model 3 Line in California\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-25 18:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.\nWorkers on a Model 3 production line in ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114131201","content_text":"Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.\nWorkers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation time, if they had it.\nRepresentatives for the Palo Alto, California-based electric carmaker didn’t immediately respond to messages seeking comment.\nWhile production-line outages aren’t unusual for automakers, they cost the companies revenue. Tesla said last month that it’strying to mitigatethe effects of a global semiconductor shortage on its operations and that it expects to increase global vehicle deliveries by more than 50% this year.\nHitting maximum deliveries is crucial for Tesla in order for Chief Executive Officer Elon Musk to meet his ambitious goal of selling 20 million cars a year by 2030. Tesla has cut the price of its various models 14 times in markets from China to Japan and France this year, spurring concern it isn’t seeing the volumes desired.\n“When considering Tesla had excess inventory in the fourth quarter of 2020, and has never been able to sell-out its production capacity, we see the company as currently demand constrained, rather than production constrained,” GLJ Research LLC founder Gordon Johnson wrote in a note earlier this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363979908,"gmtCreate":1614092302004,"gmtModify":1704888049741,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","text":"[OK] [OK] [OK] [OK]","images":[{"img":"https://static.tigerbbs.com/46e41ef5a75cec920506ef9f84aa63a2","width":"1080","height":"2157"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363979908","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363945521,"gmtCreate":1614092225763,"gmtModify":1704888048449,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363945521","repostId":"363946391","repostType":1,"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":353460824,"gmtCreate":1616513437568,"gmtModify":1704795188865,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","listText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","text":"$Mogo Finance Technology Inc.(MOGO)$like me pls","images":[{"img":"https://static.tigerbbs.com/d1eabf3a50dad90af4a39bd7c5db8334","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353460824","isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":364902905,"gmtCreate":1614789063307,"gmtModify":1704775350744,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","text":"$Tiger Brokers(TIGR)$rest , ready to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/364902905","isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341062059,"gmtCreate":1617762689971,"gmtModify":1704702790323,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","text":"$Tiger Brokers(TIGR)$like my post old haha","images":[{"img":"https://static.tigerbbs.com/d6460bc8111d6b40363d22d3f8a2998a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341062059","isVote":1,"tweetType":1,"viewCount":718,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323944336,"gmtCreate":1615301275425,"gmtModify":1704780842618,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","text":"[OK] [OK] [OK] gogo","images":[{"img":"https://static.tigerbbs.com/0186365c81b90e76d6a42357df7326ed","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323944336","isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":371159511,"gmtCreate":1618922729333,"gmtModify":1704716907339,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/371159511","repostId":"2128947843","repostType":4,"repost":{"id":"2128947843","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1618914723,"share":"https://ttm.financial/m/news/2128947843?lang=&edition=fundamental","pubTime":"2021-04-20 18:32","market":"us","language":"en","title":"Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2128947843","media":"Benzinga","summary":"Johnson &amp; Johnson (NYSE:JNJ) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.34 by 10.68 percent. This is a 12.61 percent increase over earnings of $2.30 per share from the","content":"<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-20 18:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2128947843","content_text":"Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.Johnson & Johnson Reports 2021 First-Quarter Results:- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpointFIRST-QUARTER 2021 SEGMENT COMMENTARY:Consumer HealthConsumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.PharmaceuticalPharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.Medical DevicesMedical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3557227905112544","authorId":"3557227905112544","name":"ShaunVee","avatar":"https://static.tigerbbs.com/5f64fe4fcaa4f1d2aedde844df964cb4","crmLevel":3,"crmLevelSwitch":0,"idStr":"3557227905112544","authorIdStr":"3557227905112544"},"content":"Vaccine are here to stay, they gonna earn more money In near future i guess..","text":"Vaccine are here to stay, they gonna earn more money In near future i guess..","html":"Vaccine are here to stay, they gonna earn more money In near future i guess.."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341976026,"gmtCreate":1617776262465,"gmtModify":1704702986356,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmm","listText":"hmmm","text":"hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341976026","repostId":"1162389133","repostType":4,"repost":{"id":"1162389133","pubTimestamp":1617775377,"share":"https://ttm.financial/m/news/1162389133?lang=&edition=fundamental","pubTime":"2021-04-07 14:02","market":"us","language":"en","title":"Roblox Is What Retail Investors Wish GameStop Could Be","url":"https://stock-news.laohu8.com/highlight/detail?id=1162389133","media":"InvestorPlace","summary":"RBLX stock has a model that reflects where gaming is going.Roblox(NYSE:RBLX) shot up 54% on the firs","content":"<blockquote><b>RBLX stock has a model that reflects where gaming is going.</b></blockquote><p><b>Roblox</b>(NYSE:<b><u>RBLX</u></b>) shot up 54% on the first day of trading after its direct listing. Since then, the gains have been harder to find. RBLX stock did make it as high as $77 per share, but has since come down to around $71.</p><p>Gaming has come a long way since my youth. In fact, it’s changed considerably since my children were first getting into gaming. Much of that has to do with the continued advances in artificial intelligence (AI) and augmented reality (AR). This allows gaming to become a community experience.</p><p>And it’s only going to become more immersive.</p><p>But a site like Roblox is not just controlling the way games are delivered. It has a development community that ensures it has control over the content that is delivered. Roblox has over 8 million developers that have created over 20 million experiences. This lock and key approach shows just how far behind the curve a company like<b>GameStop</b>(NYSE:<b><u>GME</u></b>) actually is.</p><p><b>A Case of Mistaken Identity</b></p><p>I’m only being partially tongue in cheek when I refer to Roblox as the company that retail investors wish GameStop was. There’s no doubt that some traders were simply driving up the price of a low-priced stock because they could. However, there is a segment of the retail trading community that believes in the long-term fortunes of GameStop.</p><p>That belief comes from the company’s new CEO, Ryan Cohen, who is the co-founder of<b>Chewy</b>(NASDAQ:<b><u>CHWY</u></b>). However, my position on GameStop and several of the “meme stocks” is that the company is going to have a difficult time making a pivot to the new world of gaming. Which isn’t really that new at all. That brings me back to Roblox.</p><p><b>A Curated Gaming Experience</b></p><p>After reading an article by<i>InvestorPlace’s</i>Tom Taulli, I see that one of thekey strengths of Robloxis the ability for developers to create worlds in which users game. Since the company’s primary audience is tweens and teenagers, the company exceeds regulatory requirements to ensure asafe gaming experience.</p><p>The idea of creating a virtual reality gaming worlds isn’t a new concept. My children (older teens and above) have informed me that Roblox is similar to<i>Minecraft</i>. They also, however, mentioned that prior to the pandemic interest in the platform was waning.</p><p>However, timing is everything. And the pandemic gave Roblox a boost. According to Roblox, the site has 37.1 million daily active users (DAUs). In 2020 those users spend a total of 30.6 billion hours on the app.</p><p>And despite the fact that we’re coming out of the pandemic, Roblox is anticipatingstrong revenue growth in 2021. It’s hard to argue that Roblox doesn’t represent the future of gaming. But you can still think it’s overvalued.</p><p><b>Institutional Investors Are Becoming Fans</b></p><p>One catalyst for RBLX stock is the endorsement of analysts and institutional investors. Roblox is already reviewed by five analysts in just one month of trading. And the consensus price target suggests that the stock could have an upside of near 15% from its current level. In fact, the lowest price target is $78 per share which would be a gain of just over 10% from the stock’s current level.</p><p>Having the big money investors in the stock this early is a double-edged sword. On the one hand, it should make the stock less volatile than some newly public companies. On the other hand, if those investors don’t like what they hear in the company’s first earnings report, RBLX stock could fall significantly.</p><p><b>You Can Wait on RBLX Stock</b></p><p>I believe there’s plenty to like about Roblox as a company. But anytime a company starts to trade publicly, it’s fair to wait until it delivers an earnings report or two.</p><p>Trust, but verify is never bad advice when you are parenting tweens and teens. And the advice holds up equally well when you’re investing in a company that markets to tweens and teens.Tastes changeand sometimes very quickly.</p><p>Nevertheless, with the backing of the analyst community, RBLX stock looks to have some upside. It’s not a stock I’m going to jump on right now, but risk tolerant investors may want to grab a small position.</p><p><img src=\"https://static.tigerbbs.com/65e38232fff6cf1f9fbcb4664faabadf\" tg-width=\"1021\" tg-height=\"499\"></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roblox Is What Retail Investors Wish GameStop Could Be</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoblox Is What Retail Investors Wish GameStop Could Be\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-07 14:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rblx-stock-what-retail-investors-thought-gamestop/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RBLX stock has a model that reflects where gaming is going.Roblox(NYSE:RBLX) shot up 54% on the first day of trading after its direct listing. Since then, the gains have been harder to find. RBLX ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rblx-stock-what-retail-investors-thought-gamestop/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"https://investorplace.com/2021/04/rblx-stock-what-retail-investors-thought-gamestop/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162389133","content_text":"RBLX stock has a model that reflects where gaming is going.Roblox(NYSE:RBLX) shot up 54% on the first day of trading after its direct listing. Since then, the gains have been harder to find. RBLX stock did make it as high as $77 per share, but has since come down to around $71.Gaming has come a long way since my youth. In fact, it’s changed considerably since my children were first getting into gaming. Much of that has to do with the continued advances in artificial intelligence (AI) and augmented reality (AR). This allows gaming to become a community experience.And it’s only going to become more immersive.But a site like Roblox is not just controlling the way games are delivered. It has a development community that ensures it has control over the content that is delivered. Roblox has over 8 million developers that have created over 20 million experiences. This lock and key approach shows just how far behind the curve a company likeGameStop(NYSE:GME) actually is.A Case of Mistaken IdentityI’m only being partially tongue in cheek when I refer to Roblox as the company that retail investors wish GameStop was. There’s no doubt that some traders were simply driving up the price of a low-priced stock because they could. However, there is a segment of the retail trading community that believes in the long-term fortunes of GameStop.That belief comes from the company’s new CEO, Ryan Cohen, who is the co-founder ofChewy(NASDAQ:CHWY). However, my position on GameStop and several of the “meme stocks” is that the company is going to have a difficult time making a pivot to the new world of gaming. Which isn’t really that new at all. That brings me back to Roblox.A Curated Gaming ExperienceAfter reading an article byInvestorPlace’sTom Taulli, I see that one of thekey strengths of Robloxis the ability for developers to create worlds in which users game. Since the company’s primary audience is tweens and teenagers, the company exceeds regulatory requirements to ensure asafe gaming experience.The idea of creating a virtual reality gaming worlds isn’t a new concept. My children (older teens and above) have informed me that Roblox is similar toMinecraft. They also, however, mentioned that prior to the pandemic interest in the platform was waning.However, timing is everything. And the pandemic gave Roblox a boost. According to Roblox, the site has 37.1 million daily active users (DAUs). In 2020 those users spend a total of 30.6 billion hours on the app.And despite the fact that we’re coming out of the pandemic, Roblox is anticipatingstrong revenue growth in 2021. It’s hard to argue that Roblox doesn’t represent the future of gaming. But you can still think it’s overvalued.Institutional Investors Are Becoming FansOne catalyst for RBLX stock is the endorsement of analysts and institutional investors. Roblox is already reviewed by five analysts in just one month of trading. And the consensus price target suggests that the stock could have an upside of near 15% from its current level. In fact, the lowest price target is $78 per share which would be a gain of just over 10% from the stock’s current level.Having the big money investors in the stock this early is a double-edged sword. On the one hand, it should make the stock less volatile than some newly public companies. On the other hand, if those investors don’t like what they hear in the company’s first earnings report, RBLX stock could fall significantly.You Can Wait on RBLX StockI believe there’s plenty to like about Roblox as a company. But anytime a company starts to trade publicly, it’s fair to wait until it delivers an earnings report or two.Trust, but verify is never bad advice when you are parenting tweens and teens. And the advice holds up equally well when you’re investing in a company that markets to tweens and teens.Tastes changeand sometimes very quickly.Nevertheless, with the backing of the analyst community, RBLX stock looks to have some upside. It’s not a stock I’m going to jump on right now, but risk tolerant investors may want to grab a small position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374051734,"gmtCreate":1619403768828,"gmtModify":1704723308172,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374051734","isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884250657,"gmtCreate":1631896562979,"gmtModify":1676530665723,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884250657","repostId":"884264656","repostType":1,"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362819137,"gmtCreate":1614611789329,"gmtModify":1704773099898,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362819137","repostId":"1161689985","repostType":4,"repost":{"id":"1161689985","pubTimestamp":1614607057,"share":"https://ttm.financial/m/news/1161689985?lang=&edition=fundamental","pubTime":"2021-03-01 21:57","market":"us","language":"en","title":"Exxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=1161689985","media":"zerohedge","summary":"Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market","content":"<blockquote><i>Could Exxon wind up being the next ESG play?</i></blockquote><p>Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, Mike Angelakis - the former CFO of Comcast and a \"green\" activist - was also said to be joining the board.</p><p>\"Mike Angelakis, the chairman and chief executive officer of Atairos and former CFO of Comcast, is also joining the board,\" CNBCreported. According toAngelakis' bio, he \"was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the Board of Directors of Duke Energy and Hewlett Packard Enterprises, and a trustee of Babson College.\"</p><p><img src=\"https://static.tigerbbs.com/c92e9846f3d968f06284115d27d81ad4\" tg-width=\"500\" tg-height=\"283\" referrerpolicy=\"no-referrer\">Two weeks agowe notedthat Ubben was looking to raise another $8 billion for his impact fund.&nbsp;Ubben was looking to raise the capital for his Spring Fund II, a successor to his $1.5 billion Spring Fund that he started while at ValueAct, which he founded in 2000, according to&nbsp;Bloomberg. The goal of the fund was reportedly going to be looking at \"impact investing\", which aims to \"make systemic changes at companies and sectors to the betterment of society.\" As we said at the time:</p><blockquote>This, of course, would fit nicely if Ubben was looking to make a major operational, ideological (and PR) shift at an undervalued legacy oil and gas company like Exxon.</blockquote><p>In early February&nbsp;we reported&nbsp;that Ubben was considering a \"meaningful stake\" in Exxon and could, as a result, even wind up with a seat on the board.</p><p><img src=\"https://static.tigerbbs.com/9b33f78346c34b0c6700782c224446fc\" tg-width=\"500\" tg-height=\"328\" referrerpolicy=\"no-referrer\"></p><p>Ubben left ValueAct last year to start his own firm that is focused on investments in social and environmental issues.</p><p><img src=\"https://static.tigerbbs.com/df87a1333f12dd2e677999e333de1888\" tg-width=\"1084\" tg-height=\"496\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-01 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"source_url":"https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161689985","content_text":"Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, Mike Angelakis - the former CFO of Comcast and a \"green\" activist - was also said to be joining the board.\"Mike Angelakis, the chairman and chief executive officer of Atairos and former CFO of Comcast, is also joining the board,\" CNBCreported. According toAngelakis' bio, he \"was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the Board of Directors of Duke Energy and Hewlett Packard Enterprises, and a trustee of Babson College.\"Two weeks agowe notedthat Ubben was looking to raise another $8 billion for his impact fund. Ubben was looking to raise the capital for his Spring Fund II, a successor to his $1.5 billion Spring Fund that he started while at ValueAct, which he founded in 2000, according to Bloomberg. The goal of the fund was reportedly going to be looking at \"impact investing\", which aims to \"make systemic changes at companies and sectors to the betterment of society.\" As we said at the time:This, of course, would fit nicely if Ubben was looking to make a major operational, ideological (and PR) shift at an undervalued legacy oil and gas company like Exxon.In early February we reported that Ubben was considering a \"meaningful stake\" in Exxon and could, as a result, even wind up with a seat on the board.Ubben left ValueAct last year to start his own firm that is focused on investments in social and environmental issues.","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":361731476,"gmtCreate":1614261074895,"gmtModify":1704769779519,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmmm","listText":"hmmmm","text":"hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/361731476","repostId":"2114131201","repostType":4,"repost":{"id":"2114131201","pubTimestamp":1614247264,"share":"https://ttm.financial/m/news/2114131201?lang=&edition=fundamental","pubTime":"2021-02-25 18:01","market":"us","language":"en","title":"Tesla Temporarily Halts Production at Model 3 Line in California","url":"https://stock-news.laohu8.com/highlight/detail?id=2114131201","media":"Bloomberg","summary":"Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.Workers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation t","content":"<p>Tesla Inc.&nbsp;has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.</p>\n<p>Workers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation time, if they had it.</p>\n<p>Representatives for the Palo Alto, California-based electric carmaker didn’t immediately respond to messages seeking comment.</p>\n<p>While production-line outages aren’t unusual for automakers, they cost the companies revenue. Tesla said last month that it’strying to mitigatethe effects of a global semiconductor shortage on its operations and that it expects to increase global vehicle deliveries by more than 50% this year.</p>\n<p>Hitting maximum deliveries is crucial for Tesla in order for Chief Executive Officer Elon Musk to meet his ambitious goal of selling 20 million cars a year by 2030. Tesla has cut the price of its various models 14 times in markets from China to Japan and France this year, spurring concern it isn’t seeing the volumes desired.</p>\n<p>“When considering Tesla had excess inventory in the fourth quarter of 2020, and has never been able to sell-out its production capacity, we see the company as currently demand constrained, rather than production constrained,” GLJ Research LLC founder Gordon Johnson wrote in a note earlier this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Temporarily Halts Production at Model 3 Line in California</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Temporarily Halts Production at Model 3 Line in California\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-25 18:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.\nWorkers on a Model 3 production line in ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-25/tesla-temporarily-halts-production-at-model-3-line-in-california?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114131201","content_text":"Tesla Inc. has told workers it will temporarily halt some production at its car assembly plant in California, according to a person familiar with the matter.\nWorkers on a Model 3 production line in Fremont were told their line would be down from Feb. 22 until March 7, said the person, who asked not to be identified because the information is private. Impacted staff were told they would be paid for Feb. 22 and Feb. 23 and not paid for Feb. 28, March 1, 2 and 3. They were advised to take vacation time, if they had it.\nRepresentatives for the Palo Alto, California-based electric carmaker didn’t immediately respond to messages seeking comment.\nWhile production-line outages aren’t unusual for automakers, they cost the companies revenue. Tesla said last month that it’strying to mitigatethe effects of a global semiconductor shortage on its operations and that it expects to increase global vehicle deliveries by more than 50% this year.\nHitting maximum deliveries is crucial for Tesla in order for Chief Executive Officer Elon Musk to meet his ambitious goal of selling 20 million cars a year by 2030. Tesla has cut the price of its various models 14 times in markets from China to Japan and France this year, spurring concern it isn’t seeing the volumes desired.\n“When considering Tesla had excess inventory in the fourth quarter of 2020, and has never been able to sell-out its production capacity, we see the company as currently demand constrained, rather than production constrained,” GLJ Research LLC founder Gordon Johnson wrote in a note earlier this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363979908,"gmtCreate":1614092302004,"gmtModify":1704888049741,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","text":"[OK] [OK] [OK] [OK]","images":[{"img":"https://static.tigerbbs.com/46e41ef5a75cec920506ef9f84aa63a2","width":"1080","height":"2157"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363979908","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363945521,"gmtCreate":1614092225763,"gmtModify":1704888048449,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363945521","repostId":"363946391","repostType":1,"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}